CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0815 (clinicaltrials.gov NCT No: NCT01208662)
Title:A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.
Principal Investigator:Michael Wang
Treatment Agent:Bortezomib; Dexamethasone; Lenalidomide; Stem Cell Transplantation
Study Status:Closed
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase III
Treatment Agents:Bortezomib
Dexamethasone
Lenalidomide
Stem Cell Transplantation
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Celgene
Millenium
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Wang
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults